By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Enterprise Replace Part 3 PALISADE Outcomes Revealed in The New England Journal of Drugs On September 2, 2024, Arrowhead Prescribed drugs, Inc. (NASDAQ:ARWR) introduced outcomes for the Part 3 PALISADE trial of plozasiran in sufferers with familial chylomicronemia syndrome (FCS). The outcomes had been … Read more
Generally, companies are frightened about producing natural visitors and staying in search engine marketing however there’s nothing to fret about. All due to native website positioning instruments. The reason being that they’ve the potential to help native on-line companies in driving an enormous natural visitors. Native companies can use native website positioning instruments to drive … Read more
By Thomas Kerr, CFA NASDAQ:HTCR READ THE FULL HTCR RESEARCH REPORT On August 14, 2024, HeartCore (NASDAQ:HTCR) reported 2nd quarter 2024 monetary outcomes which confirmed revenues beneath expectations regardless of 20% natural development within the core software program enterprise. Revenues within the quarter have been $4.1 million in comparison with $5.1 million within the 2nd … Read more